Literature DB >> 25168767

Glioma stem cells: markers, hallmarks and therapeutic targeting by metformin.

Joseph Najbauer1, Nikola Kraljik, Péter Németh.   

Abstract

Malignant gliomas are among the deadliest primary brain tumors. Despite multimodal therapy and advances in chemotherapy, imaging, surgical and radiation techniques, these tumors remain virtually incurable. Glioma stem cells may be responsible for resistance to traditional therapies and tumor recurrence. Therefore, elimination of glioma stem cells may be crucial for achieving therapeutic efficacy. Metformin, a small molecule drug widely used in the therapy of type 2 diabetes, has shown significant anti-tumor effects in patients with breast cancer and prostate cancer. Recent preclinical data suggest that metformin also has therapeutic effects against glioma. Here we review the markers and hallmarks of glioma stem cells, and the molecular mechanisms involved in therapeutic targeting of glioma stem cells by metformin.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25168767     DOI: 10.1007/s12253-014-9837-z

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   2.874


  55 in total

1.  Chemotherapy resistance of glioblastoma stem cells.

Authors:  A Eramo; L Ricci-Vitiani; A Zeuner; R Pallini; F Lotti; G Sette; E Pilozzi; L M Larocca; C Peschle; R De Maria
Journal:  Cell Death Differ       Date:  2006-02-03       Impact factor: 15.828

2.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

Authors:  Shideng Bao; Qiulian Wu; Roger E McLendon; Yueling Hao; Qing Shi; Anita B Hjelmeland; Mark W Dewhirst; Darell D Bigner; Jeremy N Rich
Journal:  Nature       Date:  2006-10-18       Impact factor: 49.962

Review 3.  Strategies for enhancing antibody delivery to the brain.

Authors:  Richard T Frank; Karen S Aboody; Joseph Najbauer
Journal:  Biochim Biophys Acta       Date:  2011-07-08

Review 4.  Metformin--mode of action and clinical implications for diabetes and cancer.

Authors:  Ida Pernicova; Márta Korbonits
Journal:  Nat Rev Endocrinol       Date:  2014-01-07       Impact factor: 43.330

5.  Diabetes, metformin, and breast cancer in postmenopausal women.

Authors:  Rowan T Chlebowski; Anne McTiernan; Jean Wactawski-Wende; JoAnn E Manson; Aaron K Aragaki; Thomas Rohan; Eli Ipp; Virginia G Kaklamani; Mara Vitolins; Robert Wallace; Marc Gunter; Lawrence S Phillips; Howard Strickler; Karen Margolis; David M Euhus
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

Review 6.  Drug penetration in solid tumours.

Authors:  Andrew I Minchinton; Ian F Tannock
Journal:  Nat Rev Cancer       Date:  2006-08       Impact factor: 60.716

Review 7.  Cells of origin in cancer.

Authors:  Jane E Visvader
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

8.  Metformin selectively affects human glioblastoma tumor-initiating cell viability: A role for metformin-induced inhibition of Akt.

Authors:  Roberto Würth; Alessandra Pattarozzi; Monica Gatti; Adirano Bajetto; Alessandro Corsaro; Alessia Parodi; Rodolfo Sirito; Michela Massollo; Cecilia Marini; Gianluigi Zona; Daniela Fenoglio; Gianmario Sambuceti; Gilberto Filaci; Antonio Daga; Federica Barbieri; Tullio Florio
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

9.  Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK.

Authors:  Atsushi Sato; Jun Sunayama; Masashi Okada; Eriko Watanabe; Shizuka Seino; Keita Shibuya; Kaori Suzuki; Yoshitaka Narita; Soichiro Shibui; Takamasa Kayama; Chifumi Kitanaka
Journal:  Stem Cells Transl Med       Date:  2012-11-15       Impact factor: 6.940

10.  Brain cancer stem cells: current status on glioblastoma multiforme.

Authors:  Sabrina Facchino; Mohamed Abdouh; Gilbert Bernier
Journal:  Cancers (Basel)       Date:  2011-03-30       Impact factor: 6.639

View more
  15 in total

Review 1.  Opportunities and challenges of radiotherapy for treating cancer.

Authors:  Dörthe Schaue; William H McBride
Journal:  Nat Rev Clin Oncol       Date:  2015-06-30       Impact factor: 66.675

2.  EMAP-II sensitize U87MG and glioma stem-like cells to temozolomide via induction of autophagy-mediated cell death and G2/M arrest.

Authors:  Qi Yu; Libo Liu; Ping Wang; Yilong Yao; Yixue Xue; Yunhui Liu
Journal:  Cell Cycle       Date:  2017-04-24       Impact factor: 4.534

3.  Effect of the interference with DRP1 expression on the biological characteristics of glioma stem cells.

Authors:  Linna Zhang; Huimei Cao; Hong Tao; Jijuan Yang; Wei Gong; Qikuan Hu
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

4.  Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response.

Authors:  Julie Sesen; Perrine Dahan; Sarah J Scotland; Estelle Saland; Van-Thi Dang; Anthony Lemarié; Betty M Tyler; Henry Brem; Christine Toulas; Elizabeth Cohen-Jonathan Moyal; Jean-Emmanuel Sarry; Nicolas Skuli
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

5.  Delivery of bevacizumab by intracranial injection: assessment in glioma model.

Authors:  Yu-Xiao Liu; Wen-Jia Liu; Hui-Ru Zhang; Zhi-Wen Zhang
Journal:  Onco Targets Ther       Date:  2018-05-08       Impact factor: 4.147

6.  Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.

Authors:  R Tian; J Wang; H Yan; J Wu; Q Xu; X Zhan; Z Gui; M Ding; J He
Journal:  Oncogene       Date:  2017-06-19       Impact factor: 9.867

7.  Metformin and Ara-a Effectively Suppress Brain Cancer by Targeting Cancer Stem/Progenitor Cells.

Authors:  Tarek H Mouhieddine; Amaly Nokkari; Muhieddine M Itani; Farah Chamaa; Hisham Bahmad; Alissar Monzer; Rabih El-Merahbi; Georges Daoud; Assaad Eid; Firas H Kobeissy; Wassim Abou-Kheir
Journal:  Front Neurosci       Date:  2015-11-23       Impact factor: 4.677

8.  Screening glioma stem cells in U251 cells based on the P1 promoter of the CD133 gene.

Authors:  Xiaofeng Wang; Lu Chen; Zhongdi Xiao; Yali Wang; Tiemei Liu; Tianfu Zhang; Yucheng Zhang
Journal:  Oncol Lett       Date:  2016-08-05       Impact factor: 2.967

9.  Inhibition of EGR1 inhibits glioma proliferation by targeting CCND1 promoter.

Authors:  Dian-Gang Chen; Bo Zhu; Sheng-Qing Lv; Hongfan Zhu; Jinliang Tang; Changlin Huang; Qingrui Li; Pu Zhou; Dong-Lin Wang; Guang-Hui Li
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15

10.  Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation.

Authors:  Zhennan Tao; Tao Li; Haiwen Ma; Yihan Yang; Chen Zhang; Long Hai; Peidong Liu; Feng Yuan; Jiabo Li; Li Yi; Luqing Tong; Yingshuai Wang; Yang Xie; Haolang Ming; Shengping Yu; Xuejun Yang
Journal:  Cell Death Dis       Date:  2018-10-18       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.